Risk factor
Very vulnerable to price shocks
Profitability factor
Good growth
About
Advanced Medical Solutions Group plc (AMS), along with its subsidiaries, specializes in the innovation, production, and worldwide distribution of advanced medical solutions. Its primary markets include wound treatment, surgical procedures, and wound closure, with a significant presence across the United Kingdom, Germany, France, wider Europe, the United States, and other international regions. The company's operations are structured into two main divisions: Surgical and Woundcare. The Surgical segment provides a comprehensive range of specialized products. These include topical tissue adhesives for sealing and closing wounds, offered under the LiquiBand brand; sutures and collagen-derived materials for surgical and dental applications, marketed as RESORBA; various collagen products; the LiquiBand Fix8 laparoscopic device designed for internally securing hernia meshes; and internal sealants available under the Seal-G and Seal-G MIST brands. Conversely, the Woundcare segment focuses on a broad spectrum of sophisticated wound management technologies. Its offerings comprise alginates, medical foams, films, fibers, hydrogels, antimicrobial dressings, and hydrocolloids, alongside a dedicated line of wound care products under the ActivHeal brand. Established in 1991, Advanced Medical Solutions Group plc maintains its corporate headquarters in Winsford, United Kingdom.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA,
Target Price
The average target price of AMS.L is 297 and suggests 6.68% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio